Public Companies
Awakn Bullish on MDMA Delivery Using Catalent’s Tablet Tech
Research results indicated positive signals.
The post Awakn Bullish on MDMA Delivery Using Catalent’s Tablet Tech appeared first on Green Market Rep…
Awakn Life Sciences Corp. (OTC: AWKNF) announced Wednesday that it completed its feasibility study on a novel method for delivering MDMA using Catalent Pharma Solutions’ orally dissolving tablet.
This research, which began in February at Catalent’s Swindon, UK, facility, explored whether MDMA remained stable using the Zydis technology and if it could be optimally absorbed before reaching the stomach.
Results were positive for MDMA absorption in the mouth.
The clinical-stage biotech firm, which specializes in addiction treatments, plans to compare this proprietary formulation against the performance of traditional oral capsule MDMA.
“We look forward to the results, and my hope is the testing will demonstrate that MDMA on Catalent’s Zydis ODT technology will improve the performance of MDMA and provide significant benefits to patients in the clinic compared to MDMA in oral capsules,” Anthony Tennyson, Awakn’s CEO, said in a statement Wednesday.
David Nutt, chief research officer at Awakn, expressed satisfaction with the study’s progress.
“We are very pleased with how the feasibility study has progressed and has given us positive data around the stability and suitability of Catalent’s Zydis technology for our novel MDMA formulation,” Nutt said. “This is an important part of our product development strategy, which aims to optimize the delivery of MDMA.”
The post Awakn Bullish on MDMA Delivery Using Catalent’s Tablet Tech appeared first on Green Market Report.
mdma otc awakn life sciences awakn research
-
Psychedelics1 week agoCybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psilocybin1 week agoCalifornia advances bill for psychedelics centers
-
Psilocybin5 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoPsychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics1 week agoRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics4 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics4 days agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression